BGBR 046
Alternative Names: BGBR-046Latest Information Update: 20 May 2026
At a glance
- Originator BeiGene
- Developer BeOne Medicines
- Class Antineoplastics
- Mechanism of Action Interleukin 15 replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 11 May 2026 BeOne Medicines terminates a phase-I clinical trials in Solid tumours (Monotherapy, Late-stage disease, Metastatic disease, Combination-therapy Inoperable/Unresectable, Second-line therapy or greater) in China (IV), due to a company business decision reflecting a strategic change in the development of BGBR 046 for advanced or metastatic solid tumors (NCT06487858)
- 25 Apr 2025 Pharmacodynamics data from a pre-clinical study in Cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 18 Jul 2024 Preclinical trials in Solid tumours in China (IV)